304 related articles for article (PubMed ID: 16166557)
1. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Krenz M; Yutzey KE; Robbins J
Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
[TBL] [Abstract][Full Text] [Related]
2. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
[TBL] [Abstract][Full Text] [Related]
3. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.
Nakamura T; Colbert M; Krenz M; Molkentin JD; Hahn HS; Dorn GW; Robbins J
J Clin Invest; 2007 Aug; 117(8):2123-32. PubMed ID: 17641779
[TBL] [Abstract][Full Text] [Related]
4. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
5. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
Edwards MA; Crombie K; Schramm C; Krenz M
J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
[TBL] [Abstract][Full Text] [Related]
6. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
7. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
[TBL] [Abstract][Full Text] [Related]
8. [SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion].
He HY; Zheng J; Li Y; Heng WJ; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):288-92. PubMed ID: 16181551
[TBL] [Abstract][Full Text] [Related]
9. SH2 domain containing protein tyrosine phosphatase 2 regulates concanavalin A-dependent secretion and activation of matrix metalloproteinase 2 via the extracellular signal-regulated kinase and p38 pathways.
Ruhul Amin AR; Oo ML; Senga T; Suzuki N; Feng GS; Hamaguchi M
Cancer Res; 2003 Oct; 63(19):6334-9. PubMed ID: 14559821
[TBL] [Abstract][Full Text] [Related]
10. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
11. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations.
Nakamura T; Gulick J; Pratt R; Robbins J
Proc Natl Acad Sci U S A; 2009 Sep; 106(36):15436-41. PubMed ID: 19706403
[TBL] [Abstract][Full Text] [Related]
12. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
[TBL] [Abstract][Full Text] [Related]
13. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
Easton JB; Royer AR; Middlemas DS
J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
[TBL] [Abstract][Full Text] [Related]
14. Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
Roberts AE; Araki T; Swanson KD; Montgomery KT; Schiripo TA; Joshi VA; Li L; Yassin Y; Tamburino AM; Neel BG; Kucherlapati RS
Nat Genet; 2007 Jan; 39(1):70-4. PubMed ID: 17143285
[TBL] [Abstract][Full Text] [Related]
15. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
[TBL] [Abstract][Full Text] [Related]
16. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
Gelb BD; Tartaglia M
Hum Mol Genet; 2006 Oct; 15 Spec No 2():R220-6. PubMed ID: 16987887
[TBL] [Abstract][Full Text] [Related]
17. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
[TBL] [Abstract][Full Text] [Related]
18. SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells.
Lundin Brockdorff J; Woetmann A; Mustelin T; Kaltoft K; Zhang Q; Wasik MA; Röpke C; Ødum N
Cytokine; 2002 Nov; 20(4):141-7. PubMed ID: 12543077
[TBL] [Abstract][Full Text] [Related]
19. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
[TBL] [Abstract][Full Text] [Related]
20. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
